Free Trial

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

Ventyx Biosciences logo
$1.41 +0.02 (+1.44%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$1.42 +0.01 (+0.71%)
As of 03/14/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Key Stats

Today's Range
$1.39
$1.44
50-Day Range
$1.39
$2.52
52-Week Range
$1.34
$8.12
Volume
365,636 shs
Average Volume
1.35 million shs
Market Capitalization
$100.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Moderate Buy

Company Overview

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Remove Ads

Ventyx Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

VTYX MarketRank™: 

Ventyx Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 514th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ventyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ventyx Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Ventyx Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ventyx Biosciences is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ventyx Biosciences is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ventyx Biosciences has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ventyx Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    11.22% of the float of Ventyx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ventyx Biosciences has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Ventyx Biosciences has recently increased by 0.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Ventyx Biosciences does not currently pay a dividend.

  • Dividend Growth

    Ventyx Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.22% of the float of Ventyx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ventyx Biosciences has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Ventyx Biosciences has recently increased by 0.76%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Ventyx Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ventyx Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for VTYX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ventyx Biosciences insiders have bought 277.33% more of their company's stock than they have sold. Specifically, they have bought $300,300.00 in company stock and sold $79,585.00 in company stock.

  • Percentage Held by Insiders

    18.18% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ventyx Biosciences' insider trading history.
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Stock News Headlines

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease
See More Headlines

VTYX Stock Analysis - Frequently Asked Questions

Ventyx Biosciences' stock was trading at $2.19 at the start of the year. Since then, VTYX stock has decreased by 35.6% and is now trading at $1.41.
View the best growth stocks for 2025 here
.

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.13.

Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

Top institutional shareholders of Ventyx Biosciences include Bank of America Corp DE (6.04%), Vestal Point Capital LP (2.83%), Point72 Asset Management L.P. (2.52%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, John Nuss, Christopher W Krueger, Sheila Gujrathi, William J Sandborn and Martin Auster.
View institutional ownership trends
.

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
2/27/2025
Today
3/14/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$14.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+606.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-192,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
0.34

Miscellaneous

Free Float
57,856,000
Market Cap
$100.65 million
Optionable
Optionable
Beta
0.58
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:VTYX) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners